J2371 HCPCS code: Injection, phenylephrine hydrochloride, 20 micrograms
J2371 is the HCPCS Level II code for injection, phenylephrine hydrochloride, 20 micrograms. In 2024 Medicare paid an average of $0.19 per service for J2371 across 7,901 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. Medicare volume rose 812% from 2023 to 2024 (866 to 7,901 services). In 2024, about 43 clinicians billed Medicare for J2371 for 119 beneficiaries.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2023-07-01 |
| Last action effective | 2023-07-01 |
Who bills J2371 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 43 |
| Medicare beneficiaries | 119 |
| States with claims | 4 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J2371, 2023–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2023 | 866 | 74 | $0.33 | $0.27 |
| 2024 | 7,901 | 119 | $0.23 | $0.19 |
States with the most J2371 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Minnesota | 1,575 | $0.11 |
| Florida | 707 | $0.01 |
| Virginia | 35 | $0.01 |
| Oklahoma | 13 | $0.01 |
What changed for J2371
- 2023-07-01: J2371 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J2371?
J2371 is the HCPCS Level II code for injection, phenylephrine hydrochloride, 20 micrograms. Short descriptor: "Inj phenylephrine hcl 20 mcg".
How much does Medicare pay for J2371?
In 2024, the average Medicare payment was $0.19 per service (average allowed $0.23).
Does Medicare cover J2371?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Related J23 codes
- J2300 — Injection, nalbuphine hydrochloride, per 10 mg
- J2305 — Injection, nitroglycerin, 5 mg
- J2310 — Injection, naloxone hydrochloride, per 1 mg
- J2311 — Injection, naloxone hydrochloride (zimhi), 1 mg
- J2312 — Injection, naloxone hydrochloride, not otherwise specified, 0.01 mg
- J2313 — Injection, naloxone hydrochloride (zimhi), 0.01 mg
- J2315 — Injection, naltrexone, depot form, 1 mg
- J2320 — Injection, nandrolone decanoate, up to 50 mg
- J2323 — Injection, natalizumab, 1 mg
- J2325 — Injection, nesiritide, 0.1 mg
- J2326 — Injection, nusinersen, 0.1 mg
- J2327 — Injection, risankizumab-rzaa, intravenous, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J2371
- Watch J2371 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J2371
Sources: CMS HCPCS Level II release October 2025; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.